TrialAnnals of the rheumatic diseases2007

Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial.

A Kavanaugh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.